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Abstract Extracellular nucleotides elicit multiple responses in
eosinophils but no information on expression of purinergic
receptors in these cells is available so far. In the present study
we show that human eosinophils express the following P2Y and
P2X subtypes: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, and P2X1,
P2X4, P2X7, whose stimulation results in intracellular Ca2+
increase and production of large amounts of reactive oxygen
intermediates. These events are stimulated or inhibited, respec-
tively, by P2 receptor agonists or antagonists. ß 2000 Feder-
ation of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Eosinophils play a key role in several diseases including
asthma [1^4], allergy [5,6] and infections by helminths [7^
10]. Physiologic functions of eosinophils are related to their
ability to produce, store and release many biologically active
molecules such as major basic protein [11] and eosinophil cat-
ionic protein [12]. Secretion of granular enzymes and produc-
tion of mediators is stimulated by di¡erent agents such as
unopsonized zymosan [13], IgG-Sepharose [14], synthetic pep-
tides mimicking soluble factors produced by bacteria, the
complement protein C5a, or the calcium ionophore A23187
[13,15]. Previous reports showed that extracellular nucleotides
elicit multiple Ca2-dependent processes in human eosino-
phils, ranging from activation of chemotaxis to secretion of
intracellular mediators such as leukotriene C4 [16^18], or N-
acetyl-L-D-glucosaminidase [19].
Extracellular nucleotides have been recognized as important
mediators in many systems, where they trigger di¡erent re-
sponses via activation of plasma membrane receptors known
as P2 purinoceptors [20,21]. On the basis of pharmacological,
functional and cloning data, two P2 receptor subfamilies are
so far recognized: P2X and P2Y [22^24].
P2X receptors are identi¢ed with plasma membrane chan-
nels selective for monovalent and divalent cations which are
directly activated by extracellular ATP without requiring hy-
drolysis of the nucleotide or generation of intracellular second
messengers [25,26]. These channels were originally identi¢ed
in mammalian sensory neurons [27], and then also found in
smooth muscle cells, mouse ¢broblasts and thymocytes [28^
30]. Stimulation of P2X receptors causes Ca2 and Na in£ux
with the accompanying plasma membrane depolarization. An
interesting member of the P2X subfamily is P2X7. This recep-
tor di¡ers from the other P2X receptors for an extended car-
boxy-terminal domain that endows P2X7 with the ability to
form large plasma membrane pores permeable to small hydro-
philic molecules [31].
P2Y receptors are seven membrane-spanning, G-protein-
coupled receptors. Their activation triggers generation of ino-
sitol 1,4,5-trisphosphate and release of Ca2 from intracellular
stores [32^36]. P2Y receptors are ubiquitous, being expressed
by monocytes, macrophages, neurons, smooth and striated
muscle cells, epithelia and endothelia.
Although di¡erent nucleotides have been shown to trigger a
Ca2 response in eosinophils, no information on P2 receptor
subtype expression is available in these cells, and besides a
recent report [37], there is no hint on the possible physiolog-
ical signi¢cance of nucleotide-dependent stimulation. Thus,
we decided to perform a functional, pharmacological and bio-
chemical characterization of P2 receptors in eosinophils.
2. Materials and methods
2.1. Reagents
ATP, UTP, CTP, GTP and adenosine were purchased from Boehr-
inger Mannheim (Mannheim, Germany). 2P,3P-(4-Benzoyl)-benzoyl-
ATP (BzATP), ATPQS, 2-methylthio-ATP, recombinant human C5a
and Ficoll were obtained from Sigma Chemical Co. (Deisenhofen,
Germany). Periodate-oxidized ATP (oATP) was a kind gift of Dr.
Stefania Hanau, University of Ferrara (Ferrara, Italy). The anti-
CD16 monoclonal antibody was from Immunotech (Marseille,
France). Immunomagnetic Dynabeads M-450 were obtained from Di-
anova (Hamburg, Germany).
2.2. Solutions
Fluorescence measurements were performed either in a saline solu-
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tion containing 125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 1 mM
Na2HPO4, 5.5 mM glucose, 5 mM NaHCO3, 1 mM CaCl2, and
20 mM HEPES (pH 7.4 with NaOH), or in a Na-free saline solution
containing 300 mM sucrose, 1 mM MgSO4, 1 mM K2HPO4, 5.5 mM
glucose, 1 mM CaCl2 and 20 mM HEPES (pH 7.4 with KOH). For
oxygen radical production, cells were maintained in Hanks’ bovine
serum albumin (BSA) solution (1 mg/ml BSA).
2.3. Measurement of Ca2+ transients
Changes in the intracellular Ca2 were measured with the £uores-
cent indicator fura-2/AM, using a Zeiss microscope (Oberkochem,
Germany) equipped with the digital £uorescence unit Atto£uor. For
fura-2/AM loading, eosinophils (1U106/ml) were incubated in Hanks’
BSA solution, in the presence of 4 WM fura-2/AM and 250 WM sul-
¢npyrazone to block £uorescent dye extrusion, and incubated at 37‡C
for 30 min. Cells were then washed twice in normal or Na-free saline
solution and plated in 24 well plates for Ca2 measurements. Ca2
transients were determined by multiple cell acquisitions with the 340/
380 excitation ratio at an emission wavelength of 505 nm, curves
shown are representatives of the whole cell population.
2.4. Eosinophil puri¢cation
Eosinophils were obtained from blood of healthy donors, and
negatively selected by magnetic separation with anti-CD16 anti-
body-conjugated Dynabeads to remove neutrophils, as previously re-
ported [61]. Purity of isolated eosinophils was s 96% (Pappenheim
staining).
2.5. Reverse transcription-polymerase chain reaction (RT-PCR)
RNA was isolated by using QIAshredder and RNeasy kits from
Qiagen GmbH (Hilden, Germany). 1 Wg/ml RNA was reverse-tran-
scribed using pd(N)6 primers and M-MLV reverse transcriptase pur-
chased from Gibco BRL (MD, USA). Control reactions in the ab-
sence of reverse transcriptase were also carried out. 2 Wl cDNA was
ampli¢ed in a PCR (35 cycles) with 1 Wl of a 20 WM primers’ mix, in a
¢nal volume of 50 Wl. The sequence speci¢c primers used for P2Y and
P2X receptors were: P2Y1 (445 bp) forward, 5P-TGCCGC-
CGTCTCCTCGTCGTTC-3P, 5P-CGCCACCACCACAATGAGCC-
ACAC-3P reverse, P2Y2 (432 bp) forward, 5P-CCTCAAGACC-
TGGAATGCGT-3P, and 5P-TGACTGAGCTGTAGGCCACG-3P
reverse primers. P2Y4 (303 bp) forward, 5P-GCCATGGCCAGTA-
CAGAGTC-3P, and 5P-GTGGTTGTGGGCTGCATAAT-3P reverse
primers. P2Y6 (392 bp) forward, 5P-GTGGCTGGCCCGTGA-
CAACC-3P, and 5P-CCGCTGCAAAGCCCTCCAATAC-3P reverse
primers. P2Y11 (238 bp) forward, 5P-GTGGTTGAGTTCC-
TGGTGGC-3P, and 5P-CCAGCAGGTTGCAGGTGAAG-3P reverse
primers. P2X1 (248 bp) forward, 5P-CGCCTTCCTCTTCGAG-
TATG-3P, and 5P-GGAAGACGTAGTCAGCCACA-3P reverse prim-
ers. P2X4 (484 bp) forward, 5P-CCTGTTCGAGTACGACACGC-3P,
and 5P-GTGTGTGTCATCCTCCACCG-3P reverse primers. P2X7
(399 bp) forward, 5P-AGATCGTGGAGAATGGAGTG-3P, and 5P-
TTCTCGTGGTGTAGTTGTGG-3P reverse primers. L2-Microglobu-
lin (259 bp), forward 5P-CCTTGAGGCTATCCAGCGTA-3P, and 5P-
GTTCACACGGCAGGCATACT-3P reverse primers. The obtained
PCR products (7 Wl+3 Wl loading bu¡er) were separated in a 1.5%
agarose, ethidium bromide-containing gel. Appropriate controls to
exclude contamination with genomic DNA were also run.
2.6. Oxygen radical production
Production of reactive oxygen intermediates by eosinophils was
determined by measuring lucigenin-dependent chemiluminescence as
previously described [38]. Brie£y, 5U104 cells were resuspended in a
200 WM lucigenin-containing Hanks’ BSA-balanced salt solution and
triggered by di¡erent stimuli. Light emission was measured for 60 min
and values were expressed as intensity integral counts.
Experiments with BAPTA/AM were performed as follows: eosino-
phils were incubated in the presence of 100 WM of the intracellular
Ca2 chelator, then rinsed two times with Hanks’ BSA and challenged
with 1 mM nucleotide.
2.7. Data presentation
Data shown are from individual experiments each replicated at least
¢ve times with similar results. Blood samples were drawn from 10
di¡erent healthy subjects. Statistical signi¢cance was assessed by the
Tuckey’s multiple comparison test (ANOVA).
3. Results
3.1. ATP and UTP trigger Ca2+ changes in human eosinophils
Stimuli as di¡erent as bacterial peptides, IgE cross-linking
agents, the complement protein C5a, recombinant human eo-
taxin and extracellular nucleotides [18,38,39] induce Ca2
changes in eosinophils and basophils. It is well known in other
cell types that ATP and other nucleotides trigger Ca2 in-
creases by stimulating purinoceptors of the P2X and P2Y
subtypes.
In human eosinophils incubated in the presence of extracel-
Fig. 1. ATP (A) induces an increase in the intracellular Ca2 of eo-
sinophils which is higher in the absence than in the presence of
extracellular Na. Eosinophils were loaded with the Ca2 indicator
fura-2/AM, as speci¢ed in Section 2, and then stimulated with ATP
in a Na-containing saline solution (A, a) or in a medium where
Na was replaced with isotonic sucrose (A, b). Sucrose solution was
also used to perform all the subsequent Ca2 measurements. B: Ki-
netics of ATP-triggered Ca2 changes in Ca2-containing (B, a) or
Ca2-free, 0.5 mM EGTA-containing medium (B, b). C: Kinetics of
UTP-triggered Ca2 changes in Ca2-containing (C, a) and Ca2-
free, 0.5 mM EGTA-containing medium (C, b). All nucleotides were
added at the concentration of 1 mM. Traces are from a single ex-
periment representative of ¢ve similar.
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lular Ca2, ATP triggered a rapid and dose-dependent Ca2
spike followed by a slowly decreasing plateau (Fig. 1A, trace
a). We and others have shown that in mouse and human
lymphocytes Na competes with Ca2 for entry through the
P2X receptor [29,40,41]. This was also the case for the ATP
receptor of human eosinophils. In Fig. 1A, trace b, cells were
stimulated with ATP in a Na-free, sucrose-containing, Ca2-
supplemented solution. Under this condition, the Ca2 rise
elicited by ATP was about twice as high as in the presence
of extracellular Na, suggesting a competition between Na
and Ca2 also in the case of the eosinophil ATP receptor. In
order to maximize the Ca2 response, the following experi-
ments, unless indicated otherwise, were performed in Na-free
medium. To discriminate whether the Ca2 rise was due to
P2Y or P2X receptor activation or both, eosinophils were
stimulated with ATP in the virtual absence of extracellular
Ca2, i.e. in a Ca2-free, 0.5 mM EGTA-containing solution.
Fig. 1B, trace b, shows that the Ca2 spike elicited by 1 mM
ATP was also present in the absence of the extracellular cat-
ion, although with a lower amplitude, an indication that eo-
sinophils express P2Y purinoceptors coupled to Ca2 release
from intracellular stores. Fig. 1C, trace a, shows that the
shape and amplitude of the Ca2 spike triggered by UTP
were similar to those elicited by ATP, a result not surprising
as at least at one P2Y receptor, P2Y2, UTP is equipotent as
ATP.
3.2. Dose-dependency curves for Ca2+ changes induced by
di¡erent nucleotides
Fig. 2 shows dose^response curves for ATP, UTP, BzATP,
and GTP. A Ca2 increase was observed at an ATP concen-
tration as low as 1 WM, and a plateau was reached at 100 WM.
The other nucleotides tested (UTP, GTP, and BzATP) were
signi¢cantly less potent than ATP. ADP, 2-methylthio-ATP,
ATPQS and CTP were also active in the high micromolar
Fig. 2. ATP, UTP, GTP, BzATP dose-dependency curves for Ca2
changes. Cells were loaded with fura-2/AM, and then stimulated
with di¡erent nucleotide concentrations, in a Na-free, Ca2-con-
taining saline solution. Data are means þ S.D. of triplicate determi-
nations.
Fig. 3. Ca2 changes induced by BzATP stimulation. Cells were
pulsed with 1 mM BzATP, either in a Ca2-containing (a) or in a
Ca 2-free, 0.5 mM EGTA-containing sucrose solution (b).
Fig. 4. E¡ects of P2X7 blockers on the ATP-induced Ca2 increase.
A: Eosinophils were pretreated with 300 WM oATP for 2 h at 37‡C,
rinsed and then challenged with ATP (A, b); A, a: controls. B and
C: KN-62 (25 nM) was added to eosinophils 10 min prior to ATP
or BzATP stimulation and left in the samples throughout the ex-
periment, b; a, controls. Nucleotide concentration was 1 mM.
Traces are from a single experiment representative of ¢ve similar.
Traces are from a single experiment representative of ¢ve similar.
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range (not shown). As reported in Fig. 3, the ATP pharmaco-
logical analogue BzATP was a Ca2 mobilizing stimulus,
however, at variance with the other nucleotides, BzATP was
an e¡ective stimulus only in the presence of extracellular Ca2
(compare Fig. 3, traces a and b). Despite an early claim that
BzATP activates P2Y receptors [42], it is now well established
that BzATP is a selective agonist for the P2X receptors
[43,44]. Thus, this experiment suggests that eosinophils ex-
press functional P2X receptors and that these receptors con-
tribute to the ATP-dependent Ca2 rise. The [Ca2]i rise can-
not be unequivocally assigned to a given P2X receptor due to
the fact that BzATP could also activate other P2X receptor
subtypes besides P2X7. We found that KL-methylene ATP was
also an agonist, albeit only at concentrations above 300 WM.
3.3. P2X receptor blockers reduced
ATP-induced Ca2+ increase
To further investigate the contribution of the P2X7 recep-
tor, we took advantage of two inhibitors, the 2P,3P-dialdehyde
ATP derivative oATP [36,43,45] and KN-62, a compound
Fig. 5. ATP completely blocks the UTP-induced Ca2 rise, both in the presence or in the absence of extracellular Ca2. Eosinophils were sub-
jected to sequential stimulation with two di¡erent nucleotides. Nucleotide concentration was 1 mM. C5a was 1037 M. A, B, C, D: Ca2-con-
taining sucrose solution; E, F, G: Ca 2-free, 0.5 mM EGTA-containing sucrose solution.
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originally described as a Ca2/calmodulin-dependent protein
kinase II inhibitor that however turned out to be a potent and
selective blocker of the human P2X7 receptor [46^48]. Pre-
treatment of eosinophils with 300 WM oATP reduced the
ATP-induced Ca2 increase (Fig. 4A). The fast initial Ca2
transient, due to a release from intracellular stores, was less
a¡ected than the second declining phase. The residual Ca2
rise in the presence of oATP is likely due to P2Y receptors, as
oATP is ine¡ective at these receptors [45]. Similarly to oATP,
KN-62 reduced the amplitude of the ATP-induced Ca2 in-
crease (Fig. 4B), while completely abrogated that due to stim-
ulation with BzATP (Fig. 4C).
3.4. ATP completely abrogated the UTP-induced Ca2+ rise
To better characterize the contribution to the Ca2 rise of
the di¡erent purinoceptor subtypes, we also performed cross-
desensitization experiments. Fig. 5A shows that ATP did not
have any e¡ects on the C5a-triggered Ca2 rise, on the con-
trary stimulation with ATP completely abrogated the Ca2
rise induced by UTP (Fig. 5B). A reduction in the amplitude
of the ATP-elicited signal was seen when eosinophils were
stimulated with UTP prior to ATP (Fig. 5C), suggesting
that ATP, di¡erently from UTP, acts at two receptor sub-
types. Finally, BzATP did not desensitize the UTP-induced
response (Fig. 5D), suggesting that the two nucleotides act
on di¡erent receptors. These ¢ndings were con¢rmed by ex-
periments performed in Ca2-free conditions (Fig. 5E,F,G). In
the absence of the extracellular cation, receptors activated by
ATP and UTP were reciprocally blocked, and again BzATP
did not interfere with the UTP-induced Ca2 increase. These
¢ndings suggest that the ATP-induced Ca2 rise was due to
the activation of both P2Y and P2X subtypes, while UTP
only activated the P2Y subtype. Good candidates for this
response are P2Y2 and P2Y4 as ATP and UTP are equipotent
at these receptors, although P2Y4 can probably be excluded
since ATP is reported to be inactive at the human P2Y4 sub-
type [49].
3.5. Human eosinophils express P2Y and P2X purinoceptor
subtypes
No antibodies against P2Y receptors are available as yet,
thus we checked receptor expression by RT-PCR. Fig. 6A
shows that human eosinophils express P2Y1, P2Y2, P2Y4,
P2Y6 and P2Y11. Fig. 6B shows that in the P2X subfamily,
only the P2X1, P2X4, and P2X7 subtypes are expressed.
3.6. Oxygen radical generation induced by extracellular
nucleotides
Stimulation of human eosinophils and neutrophils with re-
combinant eotaxin [38], or C3a [50] activates oxygen radical
(ROIs) generation. Furthermore, ATP was identi¢ed as the
soluble factor released by platelets that induces oxygen radical
production by neutrophils [51]. Therefore we asked whether
ATP could also be able to trigger the generation of oxygen
intermediates from human eosinophils. Using a lucigenin-de-
pendent assay, we show in Fig. 7 that ATP triggered the
production of ROIs to a level comparable to that obtained
with C5a (Fig. 7A). ROIs due to ATP, but not that due to
C5a, were partially blocked by oATP (Fig. 7A) and KN-62
(Fig. 7B), this inhibitor completely blocked ROIs production
due to BzATP stimulation (Fig. 7C); in support of the spe-
ci¢city of KN-62 as a P2X7 blocker, C5a- (Fig. 7C) and UTP-
stimulated production of ROIs (not shown) were not inhibited
by this antagonist. Among P1 agonists, we tested adenosine,
that however lacked any e¡ect.
Finally, we investigated whether other P2 receptors, besides
P2X, could be involved in ROIs production. Fig. 7D shows
that UTP, ATP, and GTP (C5a was used as a positive con-
trol) triggered the generation of ROIs, in the absence of extra-
cellular Ca2. This is a strong indication that also P2Y recep-
tors participate in ROIs production due to stimulation by
extracellular nucleotides. Lack of activity of BzATP under
these conditions further stresses the P2X selectivity of this
compound. The intracellular Ca2 chelator BAPTA/AM at
a concentration of 100 WM was used to check whether ATP-
induced ROIs production was mediated by an increase in the
[Ca2]i. BAPTA/AM completely obliterated ROIs generation,
showing that intracellular Ca2 was involved (not shown).
4. Discussion
ATP is released from many cell types including macro-
phages, neurons [52] platelets [53,54], endothelial cells [55],
and microglia, in physiological or pathological conditions
[56], thus leading to stimulation of multiple cell responses
such as proliferation, secretion or cell death. Responses to
ATP have been detected also in the lung. Mg-ATP has been
used to treat pulmonary hypertension in children [57], and
inhalation of aerosolized ATP has been reported to cause a
strong bronchoalveolar constriction both in normal and asth-
Fig. 6. P2 receptors expressed by human eosinophils. P2Y receptors
(A). P2X receptors (B). RT-PCR was performed as described in
Section 2.
FEBS 24399 11-12-00
D. Ferrari et al./FEBS Letters 486 (2000) 217^224 221
matic individuals [58]. Aerosolized UTP is currently used in
the therapy of cystic ¢brosis with bene¢cial e¡ects on mucin
secretion, ion/water transport and ciliary beat frequency [59].
Eosinophils massively in¢ltrate lung tissue in asthma and
allergic disease and are thought to play a central role in the
associated damage. These cells possess several mechanisms
able to cause tissue damage, among which generation of acti-
vated oxygen species is one of the most important. Local
mechanisms driving eosinophil recruitment and activation
are incompletely understood although they are clearly of the
utmost importance for the development of innovative thera-
peutic approaches to these diseases. Very little is known about
the potential role of nucleotides and nucleotide receptors in
the activation of eosinophils and in the ensuing tissue damage.
Scattered observations in the past reported an increased re-
lease of ATP by activated platelets isolated from atopic asth-
matics [60], and given the known eosinophil chemotactic e¡ect
of ATP [54], it has been postulated that this nucleotide,
among other platelet products, could contribute to lung in¢l-
tration by eosinophils in asthma. However, although eosino-
phils are known to be sensitive to ATP stimulation [18,51] no
detailed information on the nucleotide receptor subtypes ex-
pressed by human eosinophils was available until recently.
Our data show that these cells express most of the P2Y and
P2X subtypes so far cloned: P2Y1, P2Y2, P2Y4, P2Y6 and
P2Y11 ; P2X1, P2X4, and P2X7. The Ca2 changes triggered
by the di¡erent nucleotides show that P2Y and P2X receptors
are not only expressed but also functional. P2Y receptors are
well known for their coupling to phospholipase C and there-
fore to Ca2 mobilization from intracellular stores. On the
other hand, P2X receptors, that are intrinsic ion channels,
only mediate Ca2 in£ux from the extracellular milieu. The
fact that in eosinophils nucleotides elicit a Ca2 increase both
in the presence and absence of extracellular Ca2 is highly
suggestive for the presence of functional P2Y receptors on
the eosinophil plasma membrane. By the same token, the
ability of BzATP to increase Ca2 only in Ca2-containing
but not in Ca2-free medium shows that these cells also ex-
press functional P2X receptors which contribute in part to the
Ca2 rise caused by ATP. Further support to this conclusion
comes from the e¡ect of the two inhibitors, oATP and KN-62
that are chemically unrelated and di¡er widely in the mecha-
nism of action. oATP, introduced as a P2X7 inhibitor by our
laboratory 7 years ago, is an irreversible inhibitor that forms
Fig. 7. Extracellular nucleotides trigger ROIs production via P2X and P2Y receptor stimulation. ATP- but not C5a-induced ROIs secretion is
reduced by oATP (A) and KN-62 (B). BzATP-stimulated ROIs production is inhibited by KN-62 (C). ROI secretion in Ca2-free conditions
(D). 5U106 cells were incubated in 200 WM of a lucigenin-containing Hanks’ BSA-balanced salt solution and stimulated with 1 mM ATP,
BzATP, UTP, GTP, or 1037 M C5a. Incubation with oATP or KN-62 was performed as described in Fig. 4. Oxygen radical generation was
measured by light emission, as speci¢ed in Section 2. Measurements were performed for 60 min and values were expressed as intensity integral
counts.
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Schi¡’s bases with available lysines in the vicinity of the ATP
binding site. On the contrary, KN-62 is a reversible inhibitor
originally introduced as a calmodulin blocker and subse-
quently shown to powerfully inhibit the human P2X7 receptor
[46,61]. These P2X blockers partially reduced the Ca2 rise
triggered by ATP. KN-62 completely abrogated the BzATP-
dependent Ca2 rise and reduced the ATP-dependent Ca2
increase observed in the presence of extracellular Ca2, as
expected from an inhibitor that fully blocks Ca2 in£ux
through a P2X receptor but has no e¡ect on P2Y. Eosinophil
activation by extracellular ATP triggers a large production of
reactive oxygen intermediates. This process is likely mediated
through both P2Y and P2X receptors as other nucleotides (i.e.
UTP and GTP) that are P2Y but not P2X agonists are also
e¡ective, in the absence of the extracellular cation. In addi-
tion, production of oxygen intermediates was partially
blocked by oATP and almost completely abrogated by KN-
62.
It is increasingly appreciated that nucleotide receptors could
have a central role in in£ammation as they stimulate chemo-
taxis, NADPH oxidase, secretion of lysosomal enzymes and
release of in£ammatory mediators. The present observation
that eosinophils express P2 receptors and are susceptible to
activation by extracellular nucleotides is of great potential
interest as these cells are involved in diseases with a large
impact on public health, yet little is known about factors
that mediate their recruitment and activation at the sites of
in£ammation. ATP, and possibly other nucleotides, can be
released by many cells via di¡erent mechanisms: platelets se-
crete large amounts of ATP, stored in their dense granules;
endothelial and epithelial cells, that do not accumulate ATP
in a secretory compartment, release this nucleotide by a plas-
ma membrane transporter probably belonging to the ABC
family; macrophages and microglial cells also release ATP
via an unknown pathway stimulated by bacterial compounds.
Besides these non-lytic, regulated pathways, ATP is also ob-
viously released as a consequence of plasma membrane dam-
age or cell death. At in£ammatory sites it is not at all unlikely
that signi¢cant ATP concentrations build up in the extracel-
lular space to a level su⁄cient to activate P2 receptors. Eo-
sinophils, that are increased and activated in pathologic con-
ditions such as parasitic disease, asthma or allergy might
easily be exposed to high local concentrations of extracellular
nucleotides. Given that these cells express several P2Y recep-
tors in the absence of subtype-selective inhibitors, it is not
possible to precisely identify which of the P2 metabotropic
receptors is responsible for activation, although P2Y receptors
are clearly implicated both in Ca2 rise and in NADPH ox-
idase activation. On the contrary, the participation of P2X7 is
more clearly de¢ned as oATP and KN-62 signi¢cantly, albeit
incompletely, reduced the Ca2 increase and generation of
oxygen intermediates. Further e¡orts should be directed to
study how ATP and its analogues could be used in vivo to
modulate eosinophil functions in those diseases where these
cells play a major role.
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